Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01858935 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy Subjects
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT01858935 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 56 participants.
The verdict
NCT01858935, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This study is to evaluate the safety, tolerability, and pharmacokinetics of ND-L02-s0201 in normal, healthy, subjects
Interventions
- DRUG Placebo
- DRUG ND-L02-s0201 Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01858935
The ClinicalTrials.gov registry entry for NCT01858935 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01858935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01858935 about?
NCT01858935 is a clinical study titled "A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy Subjects". This study is to evaluate the safety, tolerability, and pharmacokinetics of ND-L02-s0201 in normal, healthy, subjects
What is the current status of trial NCT01858935?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2013-05. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01858935?
The interventions under investigation include: Placebo (DRUG), ND-L02-s0201 Injection (DRUG).
Who is sponsoring clinical trial NCT01858935?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.